Sionna Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
21 Hickory Dr Ste 500, Waltham, Massachu...Phone Number
(617) 819-2020Website
www.sionnatx.comRevenue
$7.4 MillionStock Symbol
SIONIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Building on over a decade of extensive research on the genetic mutations associated with CF and founded in 2019.Explore more
Sionna Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sionna Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Sionna Therapeutics has new funding data
Earning: See what the market has to say on Sionna Therapeutics recently announced quarterly report
Click to see if Sionna Therapeutics had a recent Job posting/layoffs
Sionna Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sionna Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Sionna Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Sionna Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sionna Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Sionna Therapeutics
Find more new buyers
Compare Similar Companies to Sionna Therapeutics
Compare insights from companies similar to Sionna Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sionna Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sionna Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sionna Therapeutics.
Sionna Therapeutics financials insights
Gather financial insights about Sionna Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$111M
2024
Series C
$182M
2025
Stock Offering
$190M
Sionna Therapeutics Tech Stack
A closer look at the technologies used by Sionna Therapeutics
Most Recent Scoops
Person-Based
Spending/Investment, Business Finance, Finance
Project
Sionna Therapeutics has reported that all SION-451 cohorts with SION-2222 dosed once daily were generally well-tolerated with no serious adverse events and no treatment-emergent liver function test elevations, while two participants in the twice-daily SION-2222 cohorts discontinued due to dose-limiting events that were transient, resolved without sequelae, and confounded by other factors including potential infection.
Pharmaceuticals, Clinical Operations
Project
Sionna Therapeutics has identified SION-451 twice daily plus SION-2222 once daily as its preferred dual combination and regimen based on favorable tolerability and exposure profiles observed in its phase I trial, with exposures of both drugs in the combination consistent with those observed in individual drug trials.
Pharmaceuticals, Clinical Operations
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
Person-Based
Events
Sionna Therapeutics News & Media
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sionna Therapeutics (SION) To Contact Him Directly To Discuss Their OptionsRobbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations
Robbins LLP is Investigating the Recent Stock Drop of Sionna TherapeuticsRobbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders. Why Are We...Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky
Sionna Therapeutics Shares Lost Roughly 90% of Their Value After Phase 2a PreciSION CF Trial of SION-719 Failed to Achieve Its Key Sweat Chloride Endpoint. NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Sionna Therapeutics (NASDAQ: SION) shares collapsed approximately 92% after the Company...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sionna Therapeutics
Sign Up For FreeTo access detailed company insights
Sionna Therapeutics is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Building on over a decade of extensive research on the genetic mutations associated with CF and... Read More
